This article refers to 'Implications of tricuspid regurgitation and right ventricular volume overload in patients with heart failure with preserved ejection fraction' by K.P. Kresoja et al., published in this issue on pages 1025-1035. 'The Action is in the Interaction' -Douglas Conant.Severe tricuspid valve regurgitation (TR) is identified during routine echocardiography with a prevalence ranging between 0.9% and 2.7%. 1-3 Yet, newly diagnosed severe TR has exceedingly high 1-year risks for death (40%) and heart failure (HF) hospitalization or death (54%). 3,4 Not only is worse TR severity associated with poor prognosis, but its progression from mild to severe TR is associated with worst short-term outcomes. 5 Despite the increasing recognition of this adverse valvular condition, few medical treatments exist, and surgical intervention for TR is infrequently performed with less than 5% over 5 years following diagnosis. 3,6 This observation is likely attributed to wide variations surgical practices, patient selection, and high-risk comorbidities. 7 More recently, tricuspid transcatheter edge-to-edge repair (T-TEER) has shown promise in reducing TR severity and improving quality of life among patients with prohibitive surgical risk, 8 although trial populations to date have included modest risk groups compared with real-world patients with severe TR. 3,4,8 Recent data from a large, well-characterized population with serial echocardiography demonstrated remarkable heterogeneity among patients with newly diagnosed severe TR. 3 Adverse phenotypic characteristics associated with nearly 80% 1-year risk of death included presence of severe mitral valve regurgitation, reduced left ventricular (LV) ejection fraction, liver dysfunction, and renal dysfunction. 3 Phenotypic characteristics associated with better prognosis included HF with preserved ejection fraction (HFpEF) and absence of comorbid mitral valve disease -aThe opinions expressed in this article are not necessarily those of the Editors of the European Journal of Heart Failure or of the European Society of Cardiology.